HLA-A2相关肝癌抗原肽的初步研究

目的寻找肝癌细胞表达的肿瘤抗原肽.方法应用0.2mol/Lph3.0柠檬酸缓冲液酸洗肝癌细胞系HHCC,经SephadexG-25过滤及反向高效液相色谱分离纯化,获得可与HLA-Ⅰ类分子结合的不同组分短肽.将其与抗原加工缺陷的HLA-A2+T2细胞反应,进行肿瘤细胞特异性表位测定,同时进行CTL杀伤鉴定.结果获得4个可与HLA-A2结合的组分,其中2个可以激发较强的CTL杀伤反应.结论肝癌细胞系HHCC中存在能够激发CTL特异性反应的肿瘤抗原肽,并证实上述寻找肿瘤抗原肽的技术路线具有可行性.

Study on HLA-A2 associated antigen peptide from human hepatocellular carcinoma

Aim To seek antigenic epitope binding to HLA-A2 molecules on the human hepatocellular carcinoma cells. Methods Viable hepatocellular carcinoma cell line HHCC was washed with 0.2 mol/L citric acid buffer, (pH3.0), and purified by Sephadex G-25 filtration , followed by reversed phase high performance liquid chromatography (RP-HPLC) to obtain different fractions binding to HLA-A2 . The fractions were reacted to HLA A2 positive T2 cells and specific epitopes on the T2 cells were determined. Then, cytotoxicity of CTLs to target cell was observed. Results RP-HPLC analysis showed that fourty peptides of different fractions existed on the HHCCs, four of them could bind to HLA-A2, but only two kinds of the peptides excited cytotoxic activity of CTLs. Conclusion There are tumor antigenic peptide binding to HLA-A2 on the surface of HHCC cells, which excite specific CTL response.